EULAR 2024 :中国之声!重磅研究一览

时间:2024-06-11 12:00:52   热度:37.1℃   作者:网络

6月12日至15日,2024年欧洲风湿病学大会(EULAR)将于奥地利维也纳举行。作为世界风湿病学领域的重大会议,每年的欧洲抗风湿病联盟(EULAR)年会都会吸引世界各地风湿免疫领域的专家学者共同分享最新研究成果和临床实践经验。

本次大会将会对5个既往的指南/建议进行更新,还分别针对晶体关节炎影像学诊断和治疗、有癌症病史的炎症性关节炎患者靶向治疗以及风湿病患者的疲劳管理提出了新建议。此外,共有21篇摘要或口头报告来自中国学者,内容涉及类风湿关节炎、系统性硬化症、抗磷脂综合征、皮肌炎、白塞病和痛风等多种风湿免疫疾病。本届盛会来自中国学者的重磅研究入选口头报告,这不仅彰显了我国血液学研究的广度与深度,更是我国在此领域蓬勃崛起与卓越贡献的有力证明。让我们一起来看精彩内容吧。

1. OP0026:The Efficacy and Safety of Telitacicept Following Rituximab Immunotherapy on Antiphospholipid Syndrome, A Prospective 24 weeks Study

讲者:舒强

单位:山东大学齐鲁医院

2.OP0037:A multicenter, randomized, placebo-controlled, double-blind, phase 3 study of SHR0302, a selective danus kinase 1 inhibitor, in patients with active rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs

讲者:刘金晶

单位:北京协和医院

3.OP0045:Analysis of Ovarian Dysfunction and related serological indicators in SSc

讲者:Liyi Dai

单位:北京大学第三医院

4.OP0050:Evaluating the value of superoxide dismutase in anti-MDA5-positive dermatomyositis associated with interstitial lung disease

讲者:唐琳

单位:重庆医科大学附属第二医院

5.OP0079:A Randomized, Double-Blind, Placebo-and-Tocilizumab Controlled Phase II Trial of VDJ-001, A High-Affinity IL-6R Antagonist Antibody, for the Treatment of Patients with Rheumatoid Arthritis

讲者:叶华

单位:北京大学人民医院

6.OP0083:Malignancy risk stratification and detection rate in a Hong Kong Myositis Cohort using the International Myositis Assessment and Clinical Studies Group Guideline on Cancer Screening

讲者:Iris Yan Ki Tang

单位:香港大学医学系风湿病及临床免疫学系

7.OP0115:Identification and Validation of Anti-Protein Arginine Methyltransferase 5 (PRMT5) Antibody as a Novel Propelling Antibody for Systemic Sclerosis (SSc)

讲者:Minrui Liang

单位:复旦大学附属华山医院

8.OP0121:Immune Cell Signatures of Patients with Different Subtypes of Behcet's Disease

讲者:Huijie Yuan

单位:华中科技大学附属深圳医院

9.OP0129:A 12-week, multicenter, randomized, double-blind, placebo-controlled, phase 2 study of ruzinurad (SHR4640) in combination with febuxostat for primary gout and hyperuricemia with an inadequate response to febuxostat alone Ruzinurad (SHR4640)

讲者:丁慧华

单位:上海交通大学医学院附属仁济医院

10.OP0144:Multiple Spatial Proteomics to define Endothelial Cell Phenotypes and alterations of the Vascular Niche in SSc

讲者:Minrui Liang

单位:复旦大学附属华山医院

11.OP0154:TLR2 increasing CD8+T cell cytotoxicity by activating mitophagy in primary Sjogren's syndrome

讲者:Zhou Zhou

单位:中国科学技术大学附属第一医院

12.OP0157:CCL2-CCR2 axis mediates decidual monocyte/macrophage infiltration and inflammation in obstetric antiphospholipid syndrome

讲者:Rui Gao

单位:四川大学华西第二医院

13.OP0171:Single-cell Immune Landscape of Affected Lungs from the patients with anti- MDA5-positive Dermatomyositis

讲者:张晓明

单位:中国科学院上海巴斯德研究所

14.POS0007:The nuclear receptor DAX1 regulates WNT/β-catenin signaling to promote fibroblast activation and skin fibrosis in systemic sclerosis

讲者:Lichong Shen

单位:上海交通大学医学院附属仁济医院

15. POS0471:Continuously low muscle mass contributes to worse physical function in rheumatoid arthritis patients: a 5-year follow-up study

讲者:戴冽

单位:中山大学孙逸仙纪念医院

16.POS0477:The Impact of Serum Uric Acid on All-Cause Mortality in Rheumatoid Arthritis Patients

讲者:戴冽

单位:中山大学孙逸仙纪念医院

17.POS0495:Assessing and optimizing large language models on spondyloarthritis multi-choice question answering (SpAMCQA)

讲者:Da Teng

单位:北京石油化工学院

18.POS0534:Efficacy of telitacicept in the treatment of lupus nephritis: a 52-week, multicenter observational study

讲者:Zhu Chen

单位:中国科学技术大学

19. POS0535:Comparison of telitacicept and belimumab in patients with SLE

讲者:Mian Liu

单位:南京鼓楼医院

20. POS0560:Dysfunction of alveolar epithelial cell repair in humanized pulmonary fibrosis mouse model

讲者:Zhao-Hua Li

单位:北京大学第三医院

21. POS0566:Th17/Treg imbalance during active gout attack differs between patients with early-onset gout and late-onset gout

讲者:Xiaoyu Zi

单位:山西医科大学第二医院

上一篇: NNN:多发性硬化症相关中央静脉征、皮质...

下一篇: “爱卫新征程 健康中国行”主题活动走进陕...


 本站广告